Clinical Trial Search

Primary: Frequency of Cachexia According to Modified Fearon Criteria — 173 Participants

Primary: Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE) — 0; 0; 0; 0 Participants

Primary: Uptake of Service — 10.4; 1.8 Log-ins — p=<0.0001

Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1 Participants

Primary: Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy — 96.3; 98.8; 95.2 Percentage of participants — p=< 0.001

Primary: Change in 6-minute Walk Test Distance After 24 Weeks — 45.43; 3.83 m — p=0.002

Primary: Percentage of Participants Making at Least One Critical Error at Visit 1-Primary Device Comparisons — 10; 40; 26; 34 Percentage of participants — p=0.005

Primary: Number of Seropositive Subjects for Anti-HPV-16 Antibodies at Day 1 in HPV-093 (NCT03355820) Study — 223 Participants

Primary: Short Form Chronic Respiratory Disease Questionnaire (CRQ-SF) Total Score — 4.58; 4.43 units on a scale — p=.35

Primary: Number of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens — 185; 249; 95; 238 Participants

Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes

Primary: SpO2 Percentage Specification — 1.8; 1.7; 1.6; 1.7 Percentage of SpO2

Primary: Number of Grade 3 or 4 Adverse Events — 5; 0 adverse events

Primary: Unbound Cmax: Unbound Maximum Observed Plasma Concentration for Ixazomib — 0.300; 0.478; 0.213 ng/mL

Primary: Number of Participants in Which H. Pylori Was Eradicated — 169; 170 participants